Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Solid Tumor : Neuroblastoma, rhabdomyosarcoma, Wilms tumor, retinoblastoma, adrenocortical carcinoma and carcinoid tumor
This is a phase I study of a virus called Seneca Valley Virus (NTX-010). NTX-010 is considered experimental because it has not been approved by the Food and Drug Administration (FDA). This study uses NTX-010 because it seems to work against cancer in test tubes and animals. This study does not guarantee if NTX-010 will work in people. NTX-010 has been used in only a small number of adults. NTX-010 is given in the hopes of finding a treatment that may be effective against recurrent tumors. The purpose of such studies (Phase I studies) is to find the highest dose of the drug that can be given safely to children and young adults, and to learn what its side effects are. The duration of the study will be for 22 months.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Alberto Pappo MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Referring or consulting physicians only: firstname.lastname@example.org
For all other inquiries about St. Jude Children's Research Hospital studies: email@example.com
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.